Effective Xiaflex administration for Peyronie disease involves back-to-back injections and achieving an erection with the first injection of each series. Optimizing dosage, dilution, and incorporating ...

“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.

Five-fraction SBRT showed noninferiority to conventional radiotherapy in localized prostate cancer, with 95.8% of patients free from failure at five years. SBRT offers a shorter treatment duration, ...

“Particularly [in] bladder cancer, there's 2 new drugs on the market that are exceptionally expensive, but they do provide benefit to patients,” says Geoffrey N. Sklar, MD, FACS. In this interview, ...

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that ...

Active surveillance is effective for low-risk prostate cancer, with low metastasis and mortality rates over 10 years. The study underscores the need for improved risk stratification to minimize ...

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that ...

Route of administration impacts patient compliance and convenience, influencing the choice of PD-1/PD-L1 agents. Duration of therapy affects patients' quality of life and is a key consideration in ...

The NRG-GU011 trial evaluates relugolix plus SBRT versus SBRT alone in men with PSA recurrence and PSMA-PET-detected metastases. The study addresses whether targeted radiation can delay hormone ...

Ga-PSMA and F-Fluciclovine PET/CT significantly increased radiotherapy target volumes post-prostatectomy, with F-Fluciclovine leading to more prostate bed boosts. F-Fluciclovine showed higher prostate ...

Neal Shore, MD, FACS, emphasizes the significance of the VISION and TheraP trials in supporting the FDA approval of Lutetium-177 for patients with mCRPC who have undergone androgen receptor inhibitor ...

UGN-102's NDA acceptance marks a potential first FDA-approved treatment for LG-IR-NMIBC, with a PDUFA date of June 13, 2025. The phase 3 ENVISION trial demonstrated a 79.6% complete response rate at 3 ...